Cancer antigen 125 (CA125) is the most used serum marker and the most trusted method for early detection of ovarian cancer. CD BioGlyco offers multiple highly sensitive and specific ovarian cancer assays based on CA125. We look forward to being your scientific assistant in the field of glycoproteomics.
Endometrial cancer, cervical cancer and ovarian cancer are three of the most common malignancies of the female reproductive tract. Of these three cancers, ovarian cancer, although rare, is the most lethal, primarily because approximately three-quarters of ovarian cancer cases are diagnosed at an advanced stage and the disease has spread to organs outside the ovaries. The poor prognosis for this cancer is directly attributable to the lack of sensitive and reliable screening assays and our limited understanding of its chemoresistance and recurrence mechanisms. Therefore, the establishment of appropriate early screening tests for ovarian cancer has long been sought.
One of the most commonly used protein tests for the initial detection of various types of cancer, including ovarian cancer, is based on serum levels of CA125 cancer antigen, which is a very important tumor glyco-biomarker with a normal level at 35 U/mL. This level is elevated in advanced ovarian cancer and in malignant tumors such as colon, breast, pericardium, pancreas and other epithelial cell diseases. Today, screening for ovarian cancer using CA125 is performed in combination with physical examination and its early detection is critical to achieving an effective ovarian cancer diagnosis so that treatment programs can be initiated at the onset of the disease.
Fig.1 Schematic of the sandwich immunoassay for CA125. (mAb-capture antibody; Ab-AP- alkaline phosphatase labeled detection antibody; antigen-CA125). (Al-Ogaidi, 2013)
CD BioGlyco has developed sensitive, reliable and rapid methods for detecting low levels of CA125 that are indicative of early ovarian cancer. The strategies we provide include but are not limited to:
CD BioGlyco is committed to developing new cancer glyco-biomarker assays including CA125 assay to reduce the cost of detection systems and simplify cancer screening procedures. If you have a need for glyco-biomarker detection services, please contact us for further information.